International
University of Oxford investigates potential of CBD in the treatment of psychosis
O Oxford University Department of Psychiatry received 16,5 million pounds (about 18,5 million euros) from the charitable foundation Wellcome to lead a study that will investigate the potential of CBD (cannabidiol) in the treatment of psychosis or psychotic symptoms. A Jazz Pharmaceuticals, in addition to providing funding for the trial, will also provide Epidyolex, a drug approved for the treatment of refractory epilepsy and tuberous sclerosis, free of charge.
The research will take place in 35 centers around the world, mainly in Europe and North America. The program, entitled Stratification and Treatment in Early Psychosis (STEP), involves XNUMX people and will study patients with psychosis who have not responded to conventional treatment, patients with a first episode of psychosis, and even those at high risk of psychosis. The study will focus on the use of cannabidiol (CBD), one of several chemical components found in cannabis that does not produce a feeling of intoxication, namely Epidyolex, from Jazz Pharmaceuticals, which will provide it free of charge for the trial.
STEP will aim to identify biomarkers to personalize treatment in the future.
Philip McGuire, the Oxford University professor who is leading the study, said in a statement: “Many people with psychosis are open to trying cannabidiol and previous smaller scale studies have indicated that it has beneficial effects. Cannabidiol is one of the most promising new treatments for people with psychoses.”
Oxford University Department of Psychiatry. Photo: DR
The study will explore not only the treatment of already established psychoses, but also whether CBD can prevent the onset of psychoses in high-risk individuals. "This study could provide us with a new type of treatment for psychosis and we are extremely grateful to Wellcome and Jazz Pharmaceuticals for helping us make it a reality," added McGuire.
For her part, Lynsey Bilsland, head of mental health at Wellcome, said: "This exciting program will help us find out if cannabidiol is effective in treating psychosis at various stages by testing it on a scale."
Although antipsychotics are commonly used to treat psychosis, they can have significant side effects and patients often stop taking them, and they don't work for everyone.
____________________________________________________________________________________________________
[Disclaimer: Please note that this text was originally written in Portuguese and is translated into English and other languages using an automatic translator. Some words may differ from the original and typos or errors may occur in other languages.]____________________________________________________________________________________________________
What do you do with €3 a month? Become one of our Patrons! If you believe that independent cannabis journalism is necessary, subscribe to one of the levels of our Patreon account and you will have access to unique gifts and exclusive content. If there are many of us, we can make a difference with little!
With a professional background in CAD technical drawing (2D and 3D), João Xabregas is an activist and advocate for all uses and applications of cannabis. He discovered and entered the world of cannabis during his youth, where he developed a special interest in the cultivation of the plant, which led him on a journey of self-learning through the world of cannabis that continues to this day. His adventures linked to cannabis cultivation began with the same goal as many others: to be able to guarantee the quality and eliminate any possible risks to his health of what he consumed, as well as to avoid any type of dependence on the illicit market. However, he quickly began to view the world of cannabis and everything related to it with a very different perspective. He admits the enormous passion he has for the most persecuted plant in the world and about which he is always willing to write and have a good conversation.
Farewell to the Spanish Observatory of Medicinal Cannabis
After a decade of fighting for fairer policies for patients who need access to cannabis in...
President of Infarmed, Rui Santos Ivo, elected President of the Board of Directors of EMA
Rui Santos Ivo, president of the National Authority for Medicines and Health Products IP (Infarmed), was elected president of the Board...
Review of studies reveals the importance of the Endocannabinoid System in gastrointestinal diseases
A comprehensive review of studies published in the International Journal of Molecular Sciences analyzed the influence of the endocannabinoid system (ECS) on...
EXCLUSIVE: European Union clarifies that hemp-derived CBD is permitted in cosmetics
The European Commission has responded to a request for clarification from CannaReporter® on the recent decision by Infarmed IP to withdraw from...
HHC Classified as “Schedule II” by the Commission on Narcotic Drugs and Drug Enforcement
At its session held today in Vienna, the United Nations Commission on Psychotropic Substances (CND) approved, by qualified majority, the...
Portugal: Government falls for the third time in three years and legalization of cannabis becomes increasingly difficult
Portugal's center-right government, led by Prime Minister Luis Montenegro of the PSD (Social Democratic Party) collapsed today after the...
Alan Dronkers: “HempFlax is producing the cleanest fibre in Europe (…) but it needs to move to the next level”
Few names carry as much weight in the world of hemp and cannabis as the Dronkers family. Since their...
Over the last ten years, more than 35 scientific articles on cannabis have been published
An analysis by the National Organization for the Reform of Marijuana Laws (NORML) in the US reveals that the open file...
Hexahydrocannabinol (HHC): all about its chemistry, pharmacology, effects and safety
Hexahydrocannabinol (HHC) is rapidly emerging as one of the most discussed cannabinoids in the growing world of cannabis-derived compounds.
Spannabis bids farewell to Barcelona and moves to Bilbao in 2026
Known as Europe's largest and oldest cannabis trade fair and exhibition, Spannabis, which is...
